Abstract: Methods and systems are provided for cine magnetic resonance fingerprinting (MRF). In one example, a method includes obtaining k-space data of an MRF scan of a subject, the k-space data acquired over a plurality of phases of at least one cardiac cycle of the subject, training an image reconstruction network (IRN) to output, for each phase, one or more subspace images of the subject using the k-space data, and training a parameter estimation network (PEN) to output, for each phase, a set of tissue parameter maps of the subject using the one or more subspace images output by the IRN for the corresponding phase. Upon training the IRN and the PEN, the method further includes obtaining (and displaying and/or saving in memory) a final set of tissue parameter maps of the subject for one or more or each of the plurality of phases.

Abstract: The present invention relates to method for generating a video remix, the method comprising: receiving an input video; selecting at least one excerpt from the input video, wherein an audio signal of the selected excerpt includes at least one onset; determining a plurality of sub-sequences of the at least one excerpt; and rearranging the plurality of sub-sequences according to a predetermined pattern to form the video remix.

Abstract: The technology relates to a method for detecting high-risk unstable atherosclerotic plaque in a subject, the method comprising: a) administering to the subject a magnetic resonance imaging (MRI) contrast agent capable of being activated by myeloperoxidase (MPO) in atherosclerotic plaque; b) allowing the contrast agent to be activated by myeloperoxidase in atherosclerotic plaque; c) obtaining an image of the atherosclerotic plaque from the subject using such molecular MRI, wherein enhanced imaging is indicative of unstable plaque. In some embodiments an MPO inhibitor is administered to a subject identified as having a high-risk unstable atherosclerotic plaque.

Abstract: Methods and systems generate synthetic late gadolinium enhancement (LGE) magnetic resonance images using a magnetic resonance fingerprinting (MRF) acquisition. From a single acquisition, MRF image data is obtained, including co-registered T1 and T2 tissue property maps. Different tissue regions of interest are identified, such as viable myocardium, scar, and blood and T1 and T2 values for each are determined. Based on these, different sets of pulse sequence parameters are determined, e.g., using different synthetic image contrast models receiving the MRF image data. Synthetic LGE images at different contrasts are generated as a result, including a synthetic bright-blood LGE image, a synthetic dark-blood/gray-blood LGE image, and a synthetic optimized imaged.

Abstract: Methods and systems generate synthetic late gadolinium enhancement (LGE) magnetic resonance images using a magnetic resonance fingerprinting (MRF) acquisition. From a single acquisition, MRF image data is obtained, including co-registered T1 and T2 tissue property maps. Different tissue regions of interest are identified, such as viable myocardium, scar, and blood and T1 and T2 values for each are determined. Based on these, different sets of pulse sequence parameters are determined, e.g., using different synthetic image contrast models receiving the MRF image data. Synthetic LGE images at different contrasts are generated as a result, including a synthetic bright-blood LGE image, a synthetic dark-blood/gray-blood LGE image, and a synthetic optimized imaged.

Abstract: The technology relates to a method for detecting high-risk unstable atherosclerotic plaque in a subject, the method comprising: a) administering to the subject a magnetic resonance imaging (MRI) contrast agent capable of being activated by myeloperoxidase (MPO) in atherosclerotic plaque; b) allowing the contrast agent to be activated by myeloperoxidase in atherosclerotic plaque; c) obtaining an image of the atherosclerotic plaque from the subject using such molecular MRI, wherein enhanced imaging is indicative of unstable plaque. In some embodiments an MPO inhibitor is administered to a subject identified as having a high-risk unstable atherosclerotic plaque.